Skip to main content

Month: June 2025

EnviroGold Global Engages Hatch to Advance Commercialisation of NVRO Process™

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YTK), (“EnviroGold,” or the “Company”), a clean technology company focused on reprocessing mine waste to recover precious, base, and critical metals, is pleased to announce the appointment of Hatch Pty Ltd. (“Hatch”), a leading global professional services company, to deliver a high-level process review and engineering study in support of the commercialisation of EnviroGold’s proprietary NVRO Process™. The study will be conducted in relation to a confidential client project. The Hatch engineering study is expected to be completed in the fourth quarter of 2025. EnviroGold currently has two clients advancing through phases three and four of its Rapid Deployment Pathway, which culminate in client specific demonstration plant...

Continue reading

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD) MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other...

Continue reading

Form 8.3 – [CRANEWARE PLC – 10 06 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CRANEWARE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

YY Group Expands Integrated Facility Management Portfolio with 24IFM Acquisition, Projects S$17.04 Million in Revenue from Singapore’s Multi-Billion Dollar Market

Singapore , June 11, 2025 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce the assets acquisition of the Managing Facilities Applications, which will be branded as 24IFM, marking a strategic expansion into the property and facility management sector. This move is expected to diversify YY Group’s service offerings and create a new revenue stream through application subscriptions. Enhancing Client Experience with 24IFM 24IFM, a cutting-edge property and facility management app, offers a comprehensive suite of features tailored to streamline operations for managing agents and homeowners. These include:Booking Facilities: Simplify the process of reserving property...

Continue reading

Iterum Therapeutics Announces Partnership for Commercialization Services

U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the “Agreement”) with EVERSANA Life Science Services, LLC (“EVERSANA”) for the commercialization of the Company’s approved product, ORLYNVAHTM.   Pursuant to the Agreement, EVERSANA will provide sales and commercial operations services to the Company in the United States, as well as deliver marketing, logistics, channel...

Continue reading

AGM Update

Oxford, UK – 11 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025 to date, as it continues to provide viral vector manufacturing services to a diversified portfolio of clients. The Company remains on track to deliver the outlook set out in the Preliminary Results for the year ended 31 December 2024, published on 9 April 2025. Dr. Frank Mathias, Chief Executive Officer of OXB, commented: “We have delivered strong operational performance so far in the first half of the year, reflecting disciplined execution across our global sites and sustained commercial...

Continue reading

AIP Realty Trust Announces Execution of Engagement Letter for AllTrades Transaction Concurrent Financing

VANCOUVER, British Columbia, June 11, 2025 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP”) (TSXV: AIP.U) is pleased to announce that, further to its news release filed on June 9, 2025, the Trust has entered into an engagement letter (the “Engagement Letter”) with Desjardins Capital Markets (the “Agent”) setting forth the commercial terms under which the Agent has agreed to act as the sole lead agent and bookrunner in respect of the best efforts fully marketed offering of approximately US$100,000,000 or such other amount agreed by the Agent and the Trust of securities of the Trust (“Offered Securities”) at a price per Offered Security to be determined (the “Financing”). The terms and ultimate structure of the Financing remain under consideration and subject to negotiation with the Agent. The net proceeds of the Financing...

Continue reading

NVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery

Leading Global Pharma Joins Danish Enterprises, Startups and Public Health Systems Using AI Factories to Improve Drug Discovery and HealthcareNovo Nordisk / DCAINVIDIA is collaborating with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.PARIS, June 11, 2025 (GLOBE NEWSWIRE) — NVIDIA GTC Paris at VivaTech — NVIDIA today announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk’s agreement with DCAI to use the Gefion sovereign AI supercomputer. The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development and to apply advanced simulation and physical AI technologies. “AI is essential for every industry, and there’s no other field that...

Continue reading

NVIDIA Builds World’s First Industrial AI Cloud to Advance European Manufacturing

Europe Industrial AINVIDIA builds the world’s first industrial AI cloud to enable Europe’s industrial leaders to accelerate manufacturing design, engineering and simulation.NVIDIA to Build NVIDIA DGX B200- and NVIDIA RTX PRO Server-Powered AI Cloud in Germany to Accelerate Industrial Manufacturing Applications Industrial Software Leaders Ansys, Cadence and Siemens Announce Acceleration With NVIDIA CUDA-X and AI Libraries From Design to Shop Floor Operation, BMW Group, Maserati, Schaeffler and Volvo Cars Tap NVIDIA to Speed ComputingPARIS, June 11, 2025 (GLOBE NEWSWIRE) — NVIDIA GTC Paris at VivaTech — NVIDIA today announced it is building the world’s first industrial AI cloud for European manufacturers. This Germany-based AI factory will feature 10,000 GPUs, including through NVIDIA DGX™ B200 systems and...

Continue reading

Siemens and NVIDIA Expand Partnership to Accelerate AI Capabilities in Manufacturing

Siemens and NVIDIASiemens and NVIDIA announced an expansion of their partnership to accelerate the next era of industrial AI and digitalization and enable the factory of the future.Companies Celebrate Collaboration Driving Industrial AI for Global Manufacturers Expanded Partnership to Enable AI-Powered Factories of the Future, Connecting NVIDIA AI and Accelerated Computing With the Siemens Xcelerator Platform and Products New Industrial AI Infrastructure on NVIDIA Accelerated Computing Transforms the Factory FloorPARIS, June 11, 2025 (GLOBE NEWSWIRE) — NVIDIA GTC Paris at VivaTech—Siemens and NVIDIA announced today an expansion of their partnership to accelerate the next era of industrial AI and digitalization and enable the factory of the future. “Modern manufacturers face mounting pressure to boost efficiency, enhance...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.